Sanofi aims for acne vaccine in new pact

Lured by the $3 billion acne treatment market, Sanofi Pasteur has inked a collaboration deal with with the University of California, San Diego to develop an immunological approach to fighting the skin condition.

Current treatments for acne use benzoyl peroxide and oral or topical antibiotics, which the company notes can disrupt the skin's balance and lead to more resistant forms of the bacteria. The collaboration will attempt to develop a vaccine that will neutralize Propionibacterium acnes factors in inflammation. Financial details of the two-year agreement weren't disclosed.

"This opportunity could provide an immunotherapeutic product with significant benefits and a novel mechanism of action to address an unmet medical need," noted Dr. Elias Zerhouni, president of Global R&D, in a release. "This investigational vaccine and treatment may lead to a better solution for the many who suffer from this skin disease."

- here's the Sanofi release

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.